prikaz prve stranice dokumenta Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
  Download
PDF 1.32 MB
Scientific paper - Other
Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
Angiology, 71 (2019), 2; 105-107. https://doi.org/10.1177/0003319719855165
Reiner, Željko; Sirtori, Cesare R.; Banach, Maciej; Ruscica, Massimiliano; Sahebkar, Amirhossein

Cite this document

Reiner, Ž., Sirtori, C. R., Banach, M., Ruscica, M. & Sahebkar, A. (2019). Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. Angiology, 71. (2), 105-107. doi: 10.1177/0003319719855165

Reiner, Željko, et al. "Methotrexate for Cardiovascular Risk Reduction: The Right Choice?." Angiology, vol. 71, no. 2, 2019, pp. 105-107. https://doi.org/10.1177/0003319719855165

Reiner, Željko, Cesare R. Sirtori, Maciej Banach, Massimiliano Ruscica and Amirhossein Sahebkar. "Methotrexate for Cardiovascular Risk Reduction: The Right Choice?." Angiology 71, no. 2 (2019): 105-107. https://doi.org/10.1177/0003319719855165

Reiner, Ž., et al. (2019) 'Methotrexate for Cardiovascular Risk Reduction: The Right Choice?', Angiology, 71(2), pp. 105-107. doi: 10.1177/0003319719855165

Reiner Ž, Sirtori CR, Banach M, Ruscica M, Sahebkar A. Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. Angiology [Internet]. 2019 [cited 2024 November 15];71(2):105-107. doi: 10.1177/0003319719855165

Ž. Reiner, C. R. Sirtori, M. Banach, M. Ruscica and A. Sahebkar, "Methotrexate for Cardiovascular Risk Reduction: The Right Choice?", Angiology, vol. 71, no. 2, pp. 105-107, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:635602. [Accessed: 15 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
AuthorŽeljko Reiner
AuthorCesare R. Sirtori
AuthorMaciej Banach
AuthorMassimiliano Ruscica
AuthorAmirhossein Sahebkar
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
The causative role of inflammation in atherosclerosis and cardiovascular (CV) disease (CVD) has been well established.1 Rheumatoid arthritis (RA), a condition associated with systemic inflammation, is included in the CVD risk calculation provided by an analysis of the national QRESEARCH database that included 2.3 million people.2 Furthermore, in clinical practice, the most recent European guidelines clearly state that RA enhances CVD risk independent of traditional risk factors, with a risk ratio of 1.4 and 1.5 for men and women, respectively.3 Thus, there is now considerable evidence supporting that CVD incidence is increased by about 50% in patients with RA and that one of the leading causes of increased mortality in these patients is early CVD caused by accelerated atherogenesis.4 Therefore, the Cardiovascular Inflammation Reduction Trial (CIRT) trial aimed to assess the effect of inhibiting inflammation with low-dose methotrexate (vs placebo) on the rate of CV events in coronary patients with either type 2 diabetes or metabolic syndrome
Keywords (english)
Languageenglish
Publication typeScientific paper - Other
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleAngiology
Numberingvol. 71, no. 2, pp. 105-107
p-ISSN0003-3197
DOIhttps://doi.org/10.1177/0003319719855165
URN:NBNurn:nbn:hr:184:635602
Publication2019
Document URLhttp://bib.irb.hr/1106866
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-02-18 12:56:40